Heron Therapeutics

HRTX

Market cap $213M

Heron Therapeutics, Inc. ( HRTX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Melissa Jarel - Executive Director of Legal Craig Collard - CEO & Director Mark Hensley - Executive VP & COO Ira Duarte - Executive VP & CFO Kevin Warner - Senior Vice President of Medical Affairs Strategy & Engagement William Forbes - Executive VP & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 million ZYNRELEF ® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributors APONVIE ® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate updates.

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025.

CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights.

CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect the availability and significant potential value of the Company's net operating loss carryforwards ("NOLs") and other tax attributes, which may be used to offset future taxable income. The Board unanimously approved the adoption of the Rights Plan.

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E. Hensley - Executive VP & COO Melissa Jarel - Executive Director of Legal Conference Call Participants Brandon Richard Folkes - H.C.

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.06 per share a year ago.